MedTrace Logo

Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients

NCT00342563 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2019-06-04

Study results available
· View outcomes & findings →

Summary

The purpose of the study will be to evaluate the efficacy of mecamylamine in reducing alcohol consumption in smoking and non-smoking alcohol dependent patients.

We hypothesize that mecamylamine will result in a greater reduction of alcohol consumption than placebo. We further hypothesize that mecamylamine will be effective in reducing both alcohol consumption and smoking in a subset of alcoholics who also smoke.

Conditions

  • Alcoholism

Interventions

DRUG

mecamylamine

mecamylamine 10mg/day

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Ismene Petrakis, M.D. · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31
Primary Completion
2015-07-31
Completion
2015-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00342563 on ClinicalTrials.gov